Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
Science Advances · 13.10.2023 · 9 (41)
DOI: 10.1126/sciadv.ade3816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 13.10.2023. Verfasst von Atish Mohanty und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Inherent or acquired resistance to sotorasib poses a substantialt challenge for NSCLC treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells correlated with increased expression of integrin β4 (ITGB4), a component of the focal adhesion complex. Silencing ITGB4 in tolerant cells improved sotorasib sensitivity, while overexpressing ITGB4 enhanced tolerance to sotorasib by supporting AKT-mTOR bypass signaling. Chronic treatment with sotorasib induced WNT expression and activated the WNT/β-catenin signaling pathway. Thus, silencing both ITGB4 and β-catenin significantly improved sotorasib sensitivity in tolerant, acquired, and inherently resistant cells. In addition, the proteasome inhibitor carfilzomib (CFZ) exhibited synergism with sotorasib by down-regulating ITGB4 and β-catenin expression. Furthermore, adagrasib phenocopies the combination effect of sotorasib and CFZ by suppressing KRAS activity and inhibiting cell cycle progression in inherently resistant cells. Overall, our findings unveil previously unrecognized nongenetic mechanisms underlying resistance to sotorasib and propose a promising treatment strategy to overcome resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
- Proteome Exploration Laboratory, California Institute of Technology, Pasadena, CA 91125, USA.
- Integrative Genomics Core, Beckman Research Institute, City of Hope, Monrovia, CA 91016, USA.
- Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010,USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Atish Mohanty, Jeff Jones, Brett Lomenick, Hyejin Cho, Tonya Walser, Stanley Hamilton, Isa Mambetsariev, Martin Sattler, Mohd W Nasser, Maneesh Jain, Surinder K Batra, Raffaella Soldi, Marwan Fakih, Saswat Kumar Mohanty, Avijit Mainan, Xiwei Wu, Tsui-Fen Chou, Susmita Roy, Ravi Salgia
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Mohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S. S., Guo, L., Cho, H., Li, A., Behal, A., Mirzapoiazova, T., Massarelli, E., Koczywas, M., Arvanitis, L. D., Walser, T., Villaflor, V., Hamilton, S., Mambetsariev, I., Sattler, M., …, & Salgia, R. (2023). Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Science Advances, 9(41). https://doi.org/10.1126/sciadv.ade3816
Vancouver
Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, et al. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Science Advances. 2023;9(41). doi:10.1126/sciadv.ade3816
BibTeX
@article{Mohanty2023,
author = {Mohanty, Atish and Nam, Arin and Srivastava, Saumya and Jones, Jeff and Lomenick, Brett and Singhal, Sharad S and Guo, Linlin and Cho, Hyejin and Li, Aimin and Behal, Amita and Mirzapoiazova, Tamara and Massarelli, Erminia and Koczywas, Marianna and Arvanitis, Leonidas D and Walser, Tonya and Villaflor, Victoria and Hamilton, Stanley and Mambetsariev, Isa and Sattler, Martin and Nasser, Mohd W and Jain, Maneesh and Batra, Surinder K and Soldi, Raffaella and Sharma, Sunil and Fakih, Marwan and Mohanty, Saswat Kumar and Mainan, Avijit and Wu, Xiwei and Chen, Yihong and He, Yanan and Chou, Tsui-Fen and Roy, Susmita and Orban, John and Kulkarni, Prakash and Salgia, Ravi},
title = {Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {41},
doi = {10.1126/sciadv.ade3816}
}
EUVIMED